ÎÚÑ»´«Ã½

ÎÚÑ»´«Ã½. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that the Company established its pharmaceutical marketing subsidiary, ÎÚÑ»´«Ã½ SA/NV in Belgium. ÎÚÑ»´«Ã½ SA/NV is owned by ÎÚÑ»´«Ã½ Europe Limited (Headquarters: London, President: Yutaka Tsuchiya).

Serving as the regional sales hub for Benelux (Belgium, Netherlands and Luxembourg), which is the sixth largest market in the EU, ÎÚÑ»´«Ã½ SA/NV will start marketing activities in all three Benelux countries hereafter with the focus on the anti-epileptic drugs Zonegran® and Inovelon®, as well as the non-opioid severe chronic pain agent Prialt®. In addition, ÎÚÑ»´«Ã½ SA/NV plans to start co-promotion of its Alzheimer's disease treatment Aricept® in Belgium and Luxembourg with its co-promotion partner.

ÎÚÑ»´«Ã½ plans further expansion of its business operations across Europe and will undertake “Independent Marketing” activities by using their own sales and marketing personnel, tailored for each county. ÎÚÑ»´«Ã½ SA/NV is the Company's ninth marketing subsidiary in Europe, and brings the total number of countries where ÎÚÑ»´«Ã½ undertake sales and marketing operations through its own distribution channels to 17, including; the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Belgium, Netherlands, and Luxembourg.

Through stable provision of ÎÚÑ»´«Ã½'s products, further enabled by the establishment of new subsidiaries and branches, ÎÚÑ»´«Ã½ is committed to increasing patient value and fulfilling the diverse needs of patients and their families throughout Europe.